中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2015年
13期
150-151,154
,共3页
糖尿病肾病%老年%阿托伐他汀%贝那普利
糖尿病腎病%老年%阿託伐他汀%貝那普利
당뇨병신병%노년%아탁벌타정%패나보리
Diabetic nephropathy%Gerontics%Atorvastatin%Benazepril
目的:探讨阿托伐他汀联合贝那普利治疗老年糖尿病肾病的疗效。方法将2012年1月~2014年5月本院收治的104例老年糖尿病肾病患者随机分为治疗组和对照组(各52例),对照组在常规综合治疗的基础上给予贝那普利治疗,治疗组在对照组治疗的基础上给予阿托伐他汀治疗。结果两组患者治疗后24 h尿蛋白定量、BUN及SCr较治疗前均降低(P<0.05);治疗组治疗后的24 h尿蛋白定量、SCr降低程度较对照组降低更为明显(P<0.05);治疗组总有效率为86.5%,明显优于对照组的61.5%(P<0.05)。结论阿托伐他汀联合贝那普利治疗老年糖尿病肾病疗效显著,不良反应少,值得临床推广。
目的:探討阿託伐他汀聯閤貝那普利治療老年糖尿病腎病的療效。方法將2012年1月~2014年5月本院收治的104例老年糖尿病腎病患者隨機分為治療組和對照組(各52例),對照組在常規綜閤治療的基礎上給予貝那普利治療,治療組在對照組治療的基礎上給予阿託伐他汀治療。結果兩組患者治療後24 h尿蛋白定量、BUN及SCr較治療前均降低(P<0.05);治療組治療後的24 h尿蛋白定量、SCr降低程度較對照組降低更為明顯(P<0.05);治療組總有效率為86.5%,明顯優于對照組的61.5%(P<0.05)。結論阿託伐他汀聯閤貝那普利治療老年糖尿病腎病療效顯著,不良反應少,值得臨床推廣。
목적:탐토아탁벌타정연합패나보리치료노년당뇨병신병적료효。방법장2012년1월~2014년5월본원수치적104례노년당뇨병신병환자수궤분위치료조화대조조(각52례),대조조재상규종합치료적기출상급여패나보리치료,치료조재대조조치료적기출상급여아탁벌타정치료。결과량조환자치료후24 h뇨단백정량、BUN급SCr교치료전균강저(P<0.05);치료조치료후적24 h뇨단백정량、SCr강저정도교대조조강저경위명현(P<0.05);치료조총유효솔위86.5%,명현우우대조조적61.5%(P<0.05)。결론아탁벌타정연합패나보리치료노년당뇨병신병료효현저,불량반응소,치득림상추엄。
Objective To investigate the curative effect of atorvastatin combined with benazepril in the treatment of gerontism patients with diabetic nephropathy. Methods 104 gerontism patients with diabetic nephropathy in our hospi-tal from January 2012 to May 2014 were selected,and were randomly divided into treatment group and control group, with 52 cases in each group.Benazepril was taken to control group on the basis of routine treatment,atorvastatin was tak-en to treatment group on the basis of the treatment for control group. Results After being treated,quantitation of protein-uria in 24 h urine sample,BUN and SCr was lower than that before the treatment respectively (P<0.05).Quantitation of proteinuria in 24 h urine sample and SCr of treatment group decreased more significantly than that in control group(P<0.05).The total efficiency of treatment group was 86.5%,more superior than 61.5%of control group(P<0.05). Conclusion Atorvastatin combined with benazepril is effective in the treatment of gerontism patients with diabetic nephropathy,with fewer adverse reactions,which is worthy of promotion.